Icahn pushes harder to stop Mylan&#39;s King acquisition
639540
PITTSBURGH Carl Icahn, the largest shareholder of Mylan Laboratories, is now threatening to push for new company directors to stop the generic drug maker&#39;s four (B) billion-dollar takeover bid of King Pharmaceuticals.
406523
UBS Global Asset Management told Mylan Laboratories Inc. that Mylan&#39;s proposed acquisition of King Pharmaceuticals Inc. is dilutive to Mylan shareholders and not in the best interests of the investment firm&#39;s
38488
Generic drug maker Mylan Laboratories Inc. reaffirmed on Wednesday its planned $3.37 billion purchase of King Pharmaceuticals Inc.
21639
CINCINNATI -- Billionaire investor Carl Icahn, known for challenging the management of various corporations, wants to acquire up to $500 million worth of additional shares of Federated Department Stores Inc. , the operator of Macy's and Bloomingdale's said yesterday .
272040
Billionaire investor Carl Icahn and a group of investors are opposing yet another corporate takeover. The investors, led by Icahn, have accumulated a 7 percent stake in Mylan Laboratories Inc.
505875
Carl Icahn raised his bid for Lear Corp. by 3.5 percent to $2.9 billion after opposition from investors. The auto parts maker delayed a vote on the sale again, by four days to July 16.
370304
The move raises the possibility that Carl C. Icahn, the activist investor, may be planning to agitate for change at the company.
644960
It began in July: Mylan Laboratories (nyse: MYL - news - people ) announced it would bid $4 billion in stock for King Pharmaceuticals (nyse: KG - news - people ). Investors were less than unanimously thrilled
84238
Mylan Laboratories Inc. MYL.N on  Friday said its board of directors remains committed to the  purchase of King Pharmaceuticals Inc. KG.N, despite news that  billionaire investor Carl Icahn won regulatory approval to buy  up to 11.9 percent of Mylan's shares.
655804
-- Mylan Laboratories  Inc.MYL.N on Wednesday said it was unlikely to complete its  $3.37 billion acquisition of King Pharmaceuticals Inc.KG.N at  the current price because of King's need to restate earnings.
741365
PITTSBURGH Mylan Laboratories again reiterated its commitment to the estimated four (B) billion dollar acquisition of brand-name drug maker King Pharmaceuticals despite Wall Street financier Carl Icahn upping his stake in the company.
748008
Icahn is involved in the Mylan-King Pharmaceuticals deal for his benefit only.
632050
Billionaire financier Carl Icahn has  filed for regulatory approval to buy up to $1 billion of  Temple-Inland Inc. TIN.N shares, the company said on Friday,  pushing shares in the packaging and building materials maker to  all-time highs.
591251
Billionaire financier Carl Icahn  charged ahead on Monday with a $49 per share offer for New York  office landlord Reckson Associates Realty Corp.  although  his two partners withdrew from the bidding.
161270
Billionaire investor Carl Icahn said on   Thursday he is seeking approval from shareholders of ImClone   Systems Inc. IMCL.O to remove six directors from its board,   including the chairman and the interim chief executive, and   bring in one of his own nominees.
243589
NEW YORK - Why has Carl Icahn set his sights on the relatively insignificant Mylan Laboratories, a generic drug company with just $1.5 billion in sales and a $4.3 billion market cap?
508157
A group led by the investor Carl C. Icahn has agreed to increase its bid for the Lear Corporation, the automotive supplier, by about 3.5 percent, to roughly $2.9 billion.